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Can microfocal prostate cancer be regarded as low-risk 
prostate cancer?
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Department of Urology, Yonsei University Health System, Seoul, Korea 
Purpose: Prostate specific antigen (PSA) screening for prostate cancer has become widespread, the prostate biopsy technique has 
evolved, and the occurrence of low-risk prostate cancer has been increasing. Even low-risk patients may demonstrate disease upgrading 
or upstaging. We aimed to evaluate the clinical importance of a single microfocal prostate cancer at biopsy in patients subsequently 
treated with radical prostatectomy.
Methods: A total of 337 cases of patients who underwent radical prostatectomy after prostate biopsies were retrospectively reviewed. 
Microfocal prostate cancer was defined as Gleason score 6 and a single positive core with ≤5% cancer involvement after the standard 
12-core extended biopsy.
Results: Of the 337 prostatectomy specimens, 22 (6.5%) were microfocal prostate cancer based on prostate biopsy. On final pathology, 
microfocal patients were found to have significant 45% Gleason score upgrading (P=0.02) and 27% positive surgical margins (P=0.04) 
despite low PSA, compared with the nonmicrofocal prostate cancer group. Gleason upgrading was significantly higher in the microfocal 
prostate cancer group (P=0.02), whereas Gleason downgrading was significantly higher in the nonmicrofocal prostate cancer group 
(P<0.01). Furthermore, biochemical recurrence rate was no different between microfocal and nonmicrofocal prostate cancer at mean 31 
months (P=0.18). Overall, 13 of 22 cases (53.1%) in the microfocal prostate cancer group showed Gleason upgrading or stage upgrading.
Conclusions: Based on higher rates of Gleason score upgrading or stage upgrading cases in microfocal prostate cancer group, 
compared with nonmicrofocal prostate cancer group, active surveillance should be cautiously applied to these patients.
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INTRODUCTION
Prostate specific antigen (PSA) screening for prostate cancer 
has become widespread, the prostate biopsy technique has 
evolved, and the detection of low-risk prostate cancer has 
been increasing [1]. Concerns have been expressed that the 
increased detection of indolent prostate cancer leads to pa-
tients receiving unnecessary treatment and dealing with un-
necessary side effects [2].
 Patients diagnosed with Gleason score (GS) 6 microfocal 
prostate cancer are often considered to have low-risk disease 
during initial counseling [3]. However, according to the Epstein 
criteria [4], the preoperative diagnosis of low-risk prostate 
cancer is a difficult decision to make since prostate cancer is 
a multifocal, heterogeneous disease. Some studies have re-
ported that even low-risk patients may demonstrate disease 
upgrading or upstaging [5]. 
 A strong connection between microfocal prostate cancer at 
biopsy and clinically insignificant disease would be a strong 
argument against treating these patients [6]. We aimed to 
evaluate the clinical importance of single microfocal prostate 
cancer (GS≤6) at biopsy in patients subsequently treated with 
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radical prostatectomy (RP). We characterized pathological 
stage, surgical margin, tumor volume, and PSA density in men 
with low-risk cancer and identified pretreatment clinical pa-
rameters that may predict pathological outcomes.
MATERIALS AND METHODS
1. Patients and procedure
The study was approved by the Institutional Review Board 
of our institution. From January 2002 to September 2012, 337 
cases that underwent RP after 12-core extended prostate bi-
opsies were retrospectively reviewed. Microfocal prostate can-
cer was defined as GS 6 and a single positive core with ≤5% 
cancer involvement after the 12-core biopsy. We excluded 
patients who had undergone prostate biopsy at another insti-
tution, hormone therapy, or radiation therapy before the RP.
 In all patients, serum PSA levels were obtained before 
digital rectal examination and transrectal ultrasonography. 
Clinical staging was performed according to the TNM staging 
system, and the ellipsoid formula was used to derive prostate 
volume via transrectal ultrasonography. All biopsy and RP 
specimens were reviewed by a single genitourinary patholo-
gist. All biopsy cores were individually labeled. For each bi-
opsy protocol, the number of cores involved by cancer, total 
length of tissue sampled, total length of cancer detected, and 
GS were determined. 
 Patient age, preoperative PSA level, and clinical stage were 
recorded in all patients. The RP was performed by a single 
surgeon (B.H.C.). Lymph node dissection was selectively 
performed in patients with clinical stage T3 or greater. Patho-
logical grade and stage were defined, and surgical margin 
status was noted following light microscopy examination of 
the specimen slides. The prostatectomy specimens were fixed 
overnight in 10% neutral buffered formaldehyde and coated 
with India ink. Transverse whole mount step section speci-
mens were obtained with 4-mm intervals on a plane paral-
lel to that in which transverse T2-weighted sequences were 
performed. Upstaging was defined as pathological stage T3a, 
T3b, and T4. Patients were followed postoperatively at every 
3 months for the first year and every 6 months afterward with 
serum PSA measurement. We define biochemical recurrence 
as PSA greater than 0.2 ng/mL. 
2. Statistical analysis
Statistical analyses were performed using Student t-test to 
evaluate the demographic and clinical differences between 
microfocal prostate cancer and nonmicrofocal prostate cancer 
groups. The Mann-Whitney U test was used to compare the 
microfocal tumor characteristics, including biopsy location, 
as well as pathologic findings between the disease upgrading 
or upstaging group and the other group. All P-values less than 
0.05 were considered statistically significant. The Kaplan-Mei-
er method was used to compare biochemical recurrence-free 
survival between microfocal prostate cancer and nonmicro-
focal prostate cancer. All statistical analyses were performed 
using IBM SPSS ver. 18.0 (IBM Co., Armonk, NY, USA).
RESULTS
Of the total 337 RP cases, 22 patients were diagnosed with 
microfocal prostate cancer upon biopsy. Mean age was com-
parable between both groups, and mean PSA and GS were 
5.6 ng/mL and 5.8, respectively, in the microfocal prostate 
cancer group and 13.2 ng/mL and 7.1, respectively (Table 1). 
PSA density in the microfocal prostate cancer group was sig-
nificantly lower than in nonmicrofocal prostate cancer group 
Table 1. Patient characteristics and pathological outcome
Characteristic Microfocal PCa Nonmicrofocal PCa P-value
Number 22 315
Age (yr) 63.6±7.0 (49–71) 63.5±5.8 (48–74) 0.49
PSA (ng/mL) 5.6±2.6 (2.5–11.3) 13.2±3.8 (3.2–21.7) 0.02
PSA density (ng/mL) 0.18±0.09 (0.07–0.37) 0.36±0.07 (0.10–0.78) 0.01
Prostate volume (mL) 30.2±10.5 (16.4–64.5) 36.7±11.4 (14.8–121.3) 0.48
Gleason score, mean (range) 5.8 (4–6) 7.1 (5–9) <0.01
Pathology, n (%)
PSM 6 (27.2) 45 (14.3) 0.04
GS upgrading 10 (45.4) 69 (21.9) 0.02
GS downgrading 1 (4.5) 101 (32.1) <0.01
Stage upgrading 11 (50.0) 152 (48.3) 0.55
Biochemical recurrence 3 (13.6) 56 (17.6) 0.18
Values are presented as mean±standard deviation (range) unless otherwise indicated.
PCa, prostate cancer; PSA, prostate specific antigen; PSM, positive surgical margin; GS, Gleason score.
Lee, et al. Can microfocal prostate cancer be regarded as low-risk prostate cancer?
160
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.13028
(P = 0.01) (Table 1). Among RP specimens, there were higher 
margin positive rates in the microfocal prostate cancer group 
(27.2%) than in the nonmicrofocal prostate cancer group 
(14.3%, P = 0.03). On the final pathology, microfocal patients 
were found to have 45% Gleason upgrading, 50% staging up-
grading, and 27% positive surgical margins despite low PSA. 
In addition, the rate of GS upgrading in the microfocal pros-
tate group (45.4%) was significantly higher than in the non-
microfocal prostate cancer group (21.9%, P = 0.02), whereas 
Gleason downgrading was significantly higher in the non-
microfocal prostate cancer group (P < 0.01). The biochemical 
recurrence rate was no different between microfocal and non 
microfocal prostate cancer (Table 1). However, after a mean 
postoperative follow-up of 31 months, a log-rank test of the 
Kaplan-Meier survival curves demonstrated that overall bio-
chemical recurrence-free survival rate is significant higher in 
the microfocal group compared with non microfocal group 
(Fig. 1) (P = 0.004). 
 Of the 22 cases of microfocal prostate cancer upon biopsy, 
13 cases (59.09%) showed GS upgrading or staging upgrading. 
Seven out of 13 patients with prostate cancer (53.8%) were 
detected at the foci of the apex lesion upon biopsy. Six out of 
13 GS (46.2%) or stage upgrading cases were detected with 
prostate cancer located at the apex portion of the prostate. 
However, only one case out of 9 nonupgrading cases (11.1%) 
was detected at the apex (Table 2).
DISCUSSION
PSA screening for prostate cancer has become widespread, 
and the occurrence of low-risk prostate cancer has been dra-
matically increasing [5]. Using definite therapy such as RP, 
clinically localized prostate cancer might be curatively treat-
ed, especially in low-risk prostate cancer patients. However, 
for low-risk prostate cancer patients with insignificant pros-
tate cancer, RP is obviously an overtreatment considering the 
morbidities, postoperative complications, and oncologic fea-
tures of these cases [7]. Despite the variation of the terminol-
ogy and definitions used for insignificant prostate cancer in 
the literature, the intellectual concept of insignificant prostate 
cancer is well established: a low-grade, small-volume, and 
organ-confined prostate cancer that is unlikely to be clinically 
or biologically significant without treatment [8]. There have 
been many attempts to establish criteria to predict insignifi-
cant prostate cancer before surgery, using biopsy results, PSA 
density, and PSA/free PSA ratio [9].
 The high rates of GS or staging upgrading (59.1%) in mi-
crofocal prostate cancer in this study might result from can-
cer foci (apical portion of the prostate) which were hard to 
detect lesions at taking biopsies. At the apex portion of the 
prostate gland, the peripheral zone extends anteriorly to the 
distal prostatic urethra. It may be difficult to palpate by digital 
rectal examination cancers that arise in this apico-anterior 
peripheral zone [10]. Furthermore, an apical biopsy may not 
be performed in the initial biopsy because it is widely recog-
nized as being more painful than a biopsy of the remainder 
of the prostate and difficulty in palpating by digital rectal 
examination [11]. The zonal origin of prostate cancer affects 
the pathological findings and biochemical recurrence rate 
after RP [12]. Anterior prostate cancer including apical le-
sion were not only of lower clinical stage, but they also had 
lower GS on preoperative prostate biopsy compared with 
peripheral zone tumor [12]. However, data from whole mount 
specimens showed that anterior tumors are not insignificant 
cancers [13]. Patients with anterior prostate cancers had a 
higher tumor volume and a higher rate of positive surgical 
margins than patients with peripheral prostate cancers [12]. 
Table 2. Microfocal tumor characteristics
Characteristic
GS or stage 
upgrading
Nonupgrad-
ing 
P-value
Number 13 9
Biopsy findings (location)
Apex 7 (53.8) 1 (11.1) <0.01
Lateral 5 (38.5) 6 (66.7) <0.01
Others 1 (7.7) 2 (22.2) 0.02
Pathologic findings (location)
Apex 6 (46.2) 1 (11.1) <0.01
Lateral 6 (46.2) 7 (77.8) <0.01
Others 1 (7.7) 1 (11.1) 0.12
Biochemical recurrence 3 0
Values are presented as number (%).
GS, Gleason score.
Fig. 1. Comparison of Kaplan-Meier biochemical recurrence-
free survival curves between two groups.
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Furthermore, extraprostatic extension was more likely to be 
associated with positive surgical margins for anterior prostate 
cancers than peripheral prostate cancers, suggesting that an-
terior positive margins might be clinically significant, and at 
greater risk of biochemical recurrence [14].
 In our previous study [15], insignificant prostate cancer 
based on an Epstein criteria from a prostate biopsy underesti-
mated the true nature of prostate cancer in as many as 42.1% 
of Koreans. This high inaccuracy rate of the Epstein criteria 
might result from more aggressive and poorly differentiated 
prostate cancer in Korean men, despite a low clinical stage or 
low serum PSA level [16]. Prostate cancer arising in Korean 
men that is of a predominantly high grade may be attributed 
to reduced testosterone metabolism. Hoffman et al. [17] dem-
onstrated that patients with a low serum-free testosterone 
level have an increased mean percentage of biopsies revealing 
cancer with a GS of 8 or higher, suggesting that a low serum-
free testosterone level may be a marker of more aggressive 
disease. However, in our study we do not know the exact rea-
son why the high incidence of stage migration from insignifi-
cant disease at biopsy to significant disease at final pathology 
was occurred. Additional studies from a large data would be 
needed to confirm our results. 
 When counseling patients with low grade, microfocal pros-
tate cancer on biopsy, final decision making regarding man-
agement should be guided by the sampling technique, the 
potential risk of upgrading or upstaging, and contextual con-
siderations, such as patient age and comorbidity [15]. Further 
improved biopsy sampling technique and imaging in patients 
who choose active surveillance may help minimize the risk of 
understaging and/or undergrading [18].
 There are several limitations to our study. First, the pres-
ent study consists of a relatively small number of patients; 
therefore, statistical results should be cautiously interpreted. 
Another limitation is a retrospective study design. Future pro-
spective, large cohort study should be needed to confirm our 
current results. 
 In our study, microfocal prostate cancer showed higher 
rate of Gleason upgrading compared to nonmicrofocal pros-
tate cancer. In GS or stage upgrading cases, prostate cancer 
was usually located at the apical portion. Based on higher 
rates of GS upgrading or stage upgrading cases in microfocal 
prostate cancer group, compared with nonmicrofocal pros-
tate cancer group, active surveillance should be cautiously 
applied to these patients.
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